TrialSite News followed the experimental use of Ivermectin starting with the Monash University cell culture study revealing that the anti-parasitic zaps SARS-CoV-2 in vitro—reducing it by about 5,000 times in 48 hour. We later identified that a French biotechnology company called MedinCell, which happened to be studying Ivermectin in the context of malaria, quickly pounded on both the data and the fact that it was already working with the anti-parasitic drug to commence a study on humans with COVID-19. Recently, MedinCell was in the news again.
TrialSite News was intrigued with MedinCell as they may actually have been the first group to embrace the use of Ivermectin as an investigational drug targeting SARS-CoV-2 in humans. Digital news site Born2Invest writer Angelique Moss recently visited the topic of MedinCell. Ms. Moss reported that Christophe Douat, CEO of the company detailed their ivermectin strategy. They were already conducting studies centering on malaria. But the Monash University findings stimulated their interest to invest in a clinical study.
The First to Declare an Ivermectin Program for COVID-19?
Hence, the French biotech company has embarked on a clinic...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).